American Campus Communities, Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- William Bayless
- Full Time Employees
- 3,006
- Sector
- Real Estate
- Industry
- REIT - Residential
- Address
- 12700 Hill Country Blvd Ste T-200 Austin TX United States of America 78738
- IPO Date
- Aug 12, 2004
- CIK
- 0001283630
- Website
- americancampus.com
- Similar Companies
- Business
- American Campus Communities, Inc. (ACC) is the largest developer, owner, and manager of high-quality student housing communities in the United States. The company specializes in the acquisition, design, financing, development, construction management, leasing, and operational management of student housing properties. Its core products and services include developing and managing on-campus and near-campus student housing communities, financing student housing projects, providing construction management services, and offering third-party property and development management services. ACC serves more than 90 university campuses nationwide, offering housing solutions that cater to approximately 128,000 students with a portfolio that includes owned and third-party managed properties. The company operates primarily in the U.S., with operations spanning many states and key university markets. ACC was founded in 1993 and is headquartered in Bee Cave, Texas, near Austin. In the last 1-2 years, American Campus Communities has undergone a major strategic change through its acquisition by Blackstone Core+ perpetual capital vehicles, including Blackstone Real Estate Income Trust, Inc. (BREIT) and Blackstone Property Partners (BPP), for approximately $12.8 billion, completed in 2024. This acquisition marks a significant operational and financial shift, providing ACC with increased capital resources to expand and invest in new and existing student housing assets. The company continues to focus on growth and innovation in student housing through ongoing development projects and public-private partnerships with universities. ACC has pioneered the American Campus Equity (ACE) program, an ownership model that aligns ACC as a financial and operational partner to universities in on-campus housing development. ACC remains self-managed and self-administered under its new ownership structure, aiming to leverage Blackstone’s expertise and capital to maintain its leadership in the student housing industry. ACC’s business segments include owned student housing properties, third-party management services, and third-party development services, making it a fully integrated real estate investment trust (REIT) focused exclusively on the student housing sector. The company’s portfolio consists of approximately 204 properties with about 143,000 beds under management as of mid-2025. It targets university students as its primary market, partnering directly with higher education institutions throughout the United States. Its comprehensive approach covers all aspects of the student housing lifecycle from development and financing to property and operational management, supporting the academic and personal success of its residents. Overall, American Campus Communities leverages extensive expertise in design, development, finance, construction, and property operations tailored to the student housing market, supported by a strategic partnership with Blackstone that positions it for continued industry leadership and growth. This description incorporates ACC’s main products and services, its founding and headquarters details, and the latest major corporate changes, including the Blackstone acquisition and strategic collaboration with universities through its ACE model.
Remix Therapeutics Announces Positive Data from Phase 1/2 ARIA Study of First-in-Class MYB mRNA Degrader, REM-422, in Patients with Adenoid Cystic Carcinoma (ACC) at the American Society of Clinical Oncology Annual Meeting 2026
Honda to Begin Sales of Super-ONE Compact EV
New Data Presented at ACC.26 Further Support Benefits of Vutrisiran in ATTR-CM and Potential of Zilebesiran for Hypertension Management
Data presented at ACC.26 further demonstrate the benefits of iRhythm's Zio® ambulatory ECG portfolio across multiple patient populations as company launches new digital education platform
GE HealthCare to showcase comprehensive cardiology portfolio at ACC.26, including its latest AI-enabled imaging technologies, advanced software solutions, and key collaborations
Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo
BridgeBio to Present Long-Term Efficacy and Safety Data from the ATTRibute-CM OLE Trial at the ACC Annual Scientific Sessions
Bristol Myers Squibb Reinforces Leadership in oHCM with New Camzyos (mavacamten) Data at American College of Cardiology Annual Scientific Session & Expo 2026 (ACC.26)
Merck Highlights New Data from Cardio-Pulmonary Pipeline at ACC.26 Showcasing Commitment to Advance Innovative Research
Esperion's Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia
Stellantis-backed ACC drops plans for Italian, German gigafactories, union says
InventHelp Inventor Develops New Toothbrush/Vape Pen (ACC-486)
Aker Carbon Capture: Second-Quarter and Half-year Results 2025
New Research at ACC25 Shows Daxor BVA-Identified Euvolemic Heart Failure Patients Experience 2.61 Times Better Survival
iRhythm Unveils New Real-World Data at ACC.25 Demonstrating the Benefits of Zio® Long-Term Continuous Monitoring for Arrhythmia Detection
Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025
Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology's Annual Scientific Session & Expo (ACC.25)
ACC 2025: GE HealthCare announces the U.S. launch of pivotal innovations that will help transform the cardiology care pathway
ACC.25: Bayer Presents New Investigational Heart Failure Data and Continued Portfolio Research in Chronic Kidney Disease in Type 2 Diabetes
BridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-type Transthyretin Amyloid Cardiomyopathy (ATTR-CM) from the ATTRibute-CM Study at the ACC Annual Scientific Sessions